Biogen (BIIB) Tops Q2 EPS by $2.22, Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $240.98 -0.87%
EPS Growth %: -58.0%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
FNLC, LSBK, OVLY, More
EPS Growth %: -58.0%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q2 EPS of $10.26, $2.22 better than the analyst estimate of $8.04. Revenue for the quarter came in at $3.68 billion versus the consensus estimate of $3.44 billion.
GUIDANCE:
Biogen sees FY2020 EPS of $34.00-$36.00, versus the consensus of $32.96. Biogen sees FY2020 revenue of $13.8-14.2 billion, versus the consensus of $13.94 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Integra LifeSciences (IART) Tops Q3 EPS by 3c; offers guidance
- Oceaneering (OII) Misses Q3 EPS by 9c
- Live Oak Bancshares, Inc. (LOB) Misses Q3 EPS by 14c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
